ReviewNature reviews. Genetics2013
Cancer genome-sequencing study design.
Review in Nature reviews. Genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical application of tumour-in-normal contamination assessment from whole genome sequencing.Nature communications · 2024Pooled it
- Article
- DNA sequencing in oncology: a focus group study on a duty to recontact.Future science OA · 2024Article
- MYEOV with High Frequencies of Mutations in Head and Neck Cancers Facilitates Cancer Cell Malignant Behaviors.Biochemical genetics · 2024Article
- Association of Germline Variation in Driver Genes with Breast Cancer Risk in Chilean Population.International journal of molecular sciences · 2023Article
- Liposomal DQ in Combination with Copper Inhibits ARID1A Mutant Ovarian Cancer Growth.Biomolecules · 2023Article
- Review
- A compendium of mutational cancer driver genes.Nature reviews. Cancer · 2020Review
- Integrated analysis of whole genome and transcriptome sequencing in a young patient with gastric cancer provides insights for precision therapy.Oncology letters · 2020Article
- Applying next-generation sequencing to unravel the mutational landscape in viral quasispecies.Virus research · 2020Review
- Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer.ESMO open · 2020Article
- Extended transcriptome analysis reveals genome-wide lncRNA-mediated epigenetic dysregulation in colorectal cancer.Computational and structural biotechnology journal · 2020Article
- "Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?Haematologica · 2019Article
- Cancer stem cells and nanotechnological approaches for eradication.Stem cell investigation · 2019Review
- Progress and challenges of sequencing and analyzing circulating tumor cells.Cell biology and toxicology · 2018Review
- Accurity: accurate tumor purity and ploidy inference from tumor-normal WGS data by jointly modelling somatic copy number alterations and heterozygous germline single-nucleotide-variants.Bioinformatics (Oxford, England) · 2018Article
- A database of simulated tumor genomes towards accurate detection of somatic small variants in cancer.PloS one · 2018Article
- Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia.The Journal of cell biology · 2017Article
- High-Throughput Identification of Adaptive Mutations in Experimentally Evolved Yeast Populations.PLoS genetics · 2016Article
- Validation of a multi-omics strategy for prioritizing personalized candidate driver genesOncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Discoveries from cancer genome sequencing have the potential to translate into advances in cancer prevention, diagnostics, prognostics, treatment and basic biology. Given the diversity of downstream applications, cancer genome-sequencing studies need to be designed to best fulfil specific aims. Knowledge of second-generation cancer genome-sequencing study design also facilitates assessment of the validity and importance of the rapidly growing number of published studies. In this Review, we focus on the practical application of second-generation sequencing technology (also known as next-generation sequencing) to cancer genomics and discuss how aspects of study design and methodological considerations - such as the size and composition of the discovery cohort - can be tailored to serve specific research aims.
Indexed as
Identifiers
23594910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.